GLP-1 receptor agonists × blood pressure

TrialEndocrine2017

Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure.

F Arturi et al.PubMed ↗Publisher ↗

  • Liraglutideno clear effectLower indexed end-systolic LV volume, no range given.No ranges given.

What the trial testedas reported · 2017

No range given

Reported lower indexed end-systolic LV volume, no range given

−8.00

liraglutide vs baseline

As reported

difference −8.00, no interval

Who was studied, and how

people with type 2 diabetes, in this paper

The trial randomly assignedassigned by chance

liraglutide
baseline

Reported lower indexed end-systolic LV volume, no range given−8.00

randomised

the abstract, start to end

patients (51 ± 9 vs. 43 ± 8 ml/m CONCLUSIONS: These data

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Indexed end-systolic LV volumeliraglutide vs baseline
−8.00
GLP-1 receptor agonistsBlood pressure
1 / 4

34 papers cite it

2017
2018
2019
2020
2021
2022
2023
2024
2025
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 27830456